Fierce Biotech News & Reports
WEB2 days ago · The Fierce 50 of 2024. Shining a spotlight on the people and companies who are driving meaningful change in healthcare, pharma and biotech. Ayla Ellison Sep 9, 2024 5:00am. Medtech News.
MedTech | Fierce Biotech
WEB3 days ago · The agency's researchers will conduct experiments to measure the amounts of metals that may leech out of tampons and enter the body under normal use. Conor Hale Sep 11, 2024 10:00am. Connect. The ...
Biotech | Fierce Biotech
WEBAug 20, 2024 · Shortly after a positive data drop for Eli Lilly’s efsitora, the Indianapolis-based company is again padding the case for its weekly insulin prospect. Fraiser Kansteiner Sep 11, 2024 2:05pm ...
The top biotech hubs in 2022 - Fierce Biotech
WEBBy Annalee Armstrong Jul 5, 2022 12:00am. startups real estate venture capital (VC) small biotechs. Top cities for biotechs include Boston, San Francisco, San Diego and a little corner of North ...
Pharma - Fierce Biotech
WEB2 days ago · Roche is holding out hopes that its injectable obesity prospect could eventually demonstrate 25% weight loss in late-stage trials. James Waldron Sep 11, 2024 11:45am. Connect.
Fierce Pharma Biopharma News & Insights - Fierce Biotech
WEBFierce 50 of 2024. Shining a spotlight on the people and companies who are driving meaningful change in healthcare, pharma and biotech. Ayla Ellison Sep 9, 2024 5:02am.
Sarepta pays StrideBio $48M for preclinical gene therapies
WEBNov 15, 2019 · Sarepta Therapeutics is set to pay $48 million upfront to work with StrideBio on gene therapies. The deal gives Sarepta exclusive licenses to four CNS targets, plus an option to pay a further $42. ...
Biopharma stakeholders tease market rebound after bear months
WEBSep 19, 2022 · From March 2020 to early February 2021, the index fund of small biotechs, XBI, jumped more than 140%. Both 2020 and 2021 had record levels of private financing. It was a financial period that was ...
FDA will review vibrating constipation pill from Vibrant Gastro
WEBMay 23, 2022 · Among 312 participants, 39% reported at least one additional complete bowel movement per week, compared to 22% of those given a placebo pill. Over 22% logged two or more, versus 11% in the control ...
SQZ Biotech, breaking convention, hits the NYSE with $71M IPO
WEBOct 30, 2020 · Not so for cell therapy-focused SQZ Biotech, which raised $71 million in its New York Stock Exchange debut. “We didn’t feel bound by convention by how we thought about the exchanges,” SQZ ...